share_log

TG Therapeutics | 8-K: ® TG Therapeutics Reports Second Quarter 2024 Financial Results and Raises BRIUMVI (ublituximab-xiiy) Full Year Revenue Guidance

TG Therapeutics | 8-K: ® TG Therapeutics Reports Second Quarter 2024 Financial Results and Raises BRIUMVI (ublituximab-xiiy) Full Year Revenue Guidance

TG Therapeutics | 8-K:® TG Therapeutics公布2024年第二季度财务业绩并上调了BRIUMVI(ublituximab-xiiy)全年收入指引
美股SEC公告 ·  08/06 01:13
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息